RESUME-1: A Phase III Study of Tolperisone in the Treatment of Painful, Acute Muscle Spasms of the Back

References

• Pratzel HG , AlkenRG , RammS. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain67(2–3), 417–425 (1996).
   PubMed Web of Science ®Google Scholar
• Frydrych V , OderdaG. Skeletal muscle relaxants drug class review 12:20.04 centrally acting skeletal muscle relaxants. University Utah College Pharm.12(20), 1–40 (2016).
   Google Scholar
• Rao R , PanghateA , ChandanwaleAet al. Clinical comparative study: efficacy and tolerability of tolperisone and thiocolchicoside in acute low back pain and spinal muscle spasticity. Asian Spine J.6(2), 115–122 (2012).
   PubMedGoogle Scholar
• Dulin J , KovacsL , RammSet al. Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry31, 137–142 (1998).
   PubMed Web of Science ®Google Scholar
• Stamenova P , KoytchevR , KuhnKet al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur. J. Neurol.12(6), 453–461 (2005).
   PubMed Web of Science ®Google Scholar
• Prabhoo R , KenyS , PrabhooT , SinghA , RanaR. A Phase IV observational multi-centre open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. J. Assoc. Physicians India59, 33–37 (2011).
   PubMedGoogle Scholar
• European Medicines Agency . Assessment report for tolperisone-containing medicinal products. European Medicines Agency (2013).
   Google Scholar
• Agarwal S , PatelT , ShahN , PatelBM. Corrigendum to “comparative study of therapeutic response to baclofen vs tolperisone in spasticity” [Biomed. Pharmacother. 87 (2017) 628–635]. Biomed. Pharmacother.92, 1140 (2017).
   PubMed Web of Science ®Google Scholar
• Fudin J , RaoufM. A review of skeletal muscle relaxants for pain management. Pract. Pain Manag.16(5), 1–15 (2016).
   Google Scholar
• Caron J , KayeR , WesselT , HalsethA , KayG. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine. J. Clin. Pharm. Ther.45, 774–782 (2020).
   PubMed Web of Science ®Google Scholar
• Fischer AA , ChangCH. Electromyographic evidence of paraspinal muscle spasm during sleep in patients with low back pain. Clin. J. Pain1, 147–154 (1985).
   Google Scholar
• Deyo RA , WeinsteinJN. Low back pain. N. Engl. J. Med.344(5), 363–370 (2001).
   PubMed Web of Science ®Google Scholar
• Toth PP , UrtisJ. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin. Ther.26(9), 1355–1367 (2004).
   PubMed Web of Science ®Google Scholar
• Bratton RL . Assessment and management of acute low back pain. Am. Fam. Physician60(8), 2299–2308 (1999).
   PubMed Web of Science ®Google Scholar
• Chang E , GhoshN , YanniD , LeeS , AlexandruD , MozaffarT. A review of spasticity treatments: pharmacological and interventional approaches. Crit. Rev. Phys. Rehabil. Med.25(1–2), 11–122 (2013).
   PubMedGoogle Scholar
• Chou R . In the clinic. Low back pain. Ann. Intern. Med.160(11), ITC6-1 (2014).
   PubMed Web of Science ®Google Scholar
• Frymoyer JD . Back pain and sciatica. N. Engl. J. Med.318(5), 291–300 (1988).
   PubMed Web of Science ®Google Scholar
• Patel AT , OgleAA. Diagnosis and management of acute low back pain. Am. Fam. Physician61(6), 1779–1790 (2000).
   PubMed Web of Science ®Google Scholar
• Hoy D , BainC , WilliamsGet al. A systematic review of the global prevalence of low back pain. Arthritis Rheum.64(6), 2028–2037 (2012).
   PubMed Web of Science ®Google Scholar
• Hart LG , DeyoRA , CherkinDC. Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine20, 11–19 (1995).
   PubMed Web of Science ®Google Scholar
• Kuritzky L , CarpenterD. The primary care approach to low back pain. Prim. Care Rep.1, 29–38 (1995).
   Google Scholar
• Schappert SM . Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Stat. 13143, i-39 (1999).
   Google Scholar
• Chou R , QaseemA , SnowVet al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann. Intern. Med.147(7), 478–491 (2007).
   PubMed Web of Science ®Google Scholar
• McCarberg BH , RuoffGE , Tenzer-IglesiasP , WeilAJ. Diagnosis and treatment of low-back pain because of paraspinous muscle spasm: a physician roundtable. Pain Med.12(Suppl. 4), S119–S127 (2011).
   PubMedGoogle Scholar
• White KL , WilliamsTF , GreenbergBG. The ecology of medical care. N. Engl. J. Med.265, 885–892 (1961).
   PubMed Web of Science ®Google Scholar
• Staiger TO , PaauwDS , DeyoRA , JarvikJG. Imaging studies for acute low back pain: when and when not to order them. Postgrad. Med.105, 161–172 (1999).
   PubMed Web of Science ®Google Scholar
• Browning R , JacksonJL , O’MalleyPG. Cyclobenzaprine and back pain: a meta-analysis. Arch. Intern. Med.161(13), 1613–1620 (2001).
   PubMedGoogle Scholar
• Andersson GB , SvenssonHO , OdenA. The intensity of work recovery in low back pain. Spine8, 880–884 (1983).
   PubMed Web of Science ®Google Scholar
• Von Korff M , SaundersK. The course of back pain in primary care. Spine21(24), 2833–2837 (1996).
   PubMed Web of Science ®Google Scholar
• Nachemson AL . Newest knowledge of low back pain. A critical look. Clin. Orthop. Relat. Res.279, 8–20 (1992).
   PubMed Web of Science ®Google Scholar
• Wipf JE , DeyoRA. Low back pain. Med. Clin. North Am.79(2), 231–246 (1995).
   PubMed Web of Science ®Google Scholar
• Lim S , VosT , FlaxmanAet al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380, 2224–2260 (2012).
   PubMed Web of Science ®Google Scholar
• Vos T , FlaxmanAD , NaghaviMet al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380, 2163–2196 (2012).
   PubMed Web of Science ®Google Scholar
• Ferguson SA , MerryweatherA , TheseMSet al. Prevalence of low back pain, seeking medical care, and lost time due to low back pain among manual material handling workers in the United States. BMC Musculoskelet. Disord.20, 243 (2019).
   PubMed Web of Science ®Google Scholar
• Atlas SJ , DeyoRA. Evaluating and managing acute low back pain in the primary care setting. J. Gen. Intern. Med.16(2), 120–131 (2001).
   PubMed Web of Science ®Google Scholar
• Deyo RA , CherkinDC , ConradD , VolinnE. Cost, controversy, crisis: low back pain and health of the public. Annu. Rev. Pub. Health12, 141–156 (1991).
   PubMed Web of Science ®Google Scholar
• Borenstein DG . Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr. Opin. Rheumatol.9, 144–150 (1997).
   PubMedGoogle Scholar
• Kent PM , KeatingJL. The epidemiology of low back pain in primary care. Chiropr. Osteopat.13, 13 (2005).
   PubMedGoogle Scholar
• Pransky G , BuchbinderR , HaydenJ. Contemporary low back pain research – and implications for practice. Best Pract. Res. Clin. Rheumatol.24(2), 291–298 (2010).
   PubMed Web of Science ®Google Scholar
• Tekes K . Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med. Chem. J.8, 17–22 (2014).
   PubMedGoogle Scholar
• Nádor K , PorszászJ. Pharmakologische und pharmakochemische studien über β- aminoketone. Arzneim. Forsch.8, 313 (1958).
   PubMedGoogle Scholar
• Pórszász J , NádorK , GibiszerK , BarankayT. The pharmacology of Mydeton (Mydocalm,1-piperidino-2-methyl-3-p-tolylpropanone-3), a new interneurone blocking compound. Acta Physiol. Hung.18, 149–170 (1960).
   Google Scholar
• Novales-Li P , SunXP , TakeuchiH. Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur. J. Pharmacol.168(3), 299–305 (1989).
   PubMed Web of Science ®Google Scholar
• Ono H , FukudaH , KudoY. Mechanisms of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J. Pharmacobiodyn.7(3), 171–176 (1984).
   PubMedGoogle Scholar
• Fujioka M , KuriyamaH. Eperisone, an antispastic agent, possesses vasodilating actions on the guinea-pig basilar artery. J. Pharmacol. Exp. Ther.235(3), 757–763 (1985).
   PubMed Web of Science ®Google Scholar
• Farkas S , TarnawaI , BerzsenyiP. Effects of some centrally acting muscle relaxants on spinal root potentials: a comparative study. Neuropharmacology28(2), 161–173 (1989).
   PubMed Web of Science ®Google Scholar
• Novales-Li P . Piperidinopropiophenone derivatives as calcium antagonists in neuronal cells. Philip. J. Sci.122(3), 289–290 (1993).
   Google Scholar
• Sakitama K , OzawaY , AotoN , NakamuraK , IshikawaM. Pharmacological properties of NK433, a new centrally acting muscle relaxant. Eur. J. Pharmacol.273(1–2), 47–56 (1995).
   PubMed Web of Science ®Google Scholar
• Okada H , HondaM , OnoH. Method for recording spinal reflexes in mice: effects of thyrotropin-releasing hormone, DOI, tolperisone and baclofen on monosynaptic spinal reflex potentials. Jpn J. Pharmacol.86(1), 134–136 (2001).
   PubMedGoogle Scholar
• Kocsis P , FarkasS , FodorLet al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J. Pharmacol. Exp. Ther.315(3), 1237–4 (2005).
   PubMed Web of Science ®Google Scholar
• Hofer D , LohbergerB , SteineckerB , SchmidtK , QuasthoffS , SchreibmayerW. A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms. Eur. J. Pharmacol.538(1–3), 5–14 (2006).
   PubMed Web of Science ®Google Scholar
• Quasthoff S , MockelC , ZieglgansbergerWet al. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci. Ther.14, 107–119 (2008).
   PubMed Web of Science ®Google Scholar
• Sakaue A , HondaM , TanabeM , OnoH. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. J. Pharmacol. Sci.95(2), 181–188 (2004).
   PubMed Web of Science ®Google Scholar
• Nalamachu S , PergolizziJ , KayeR. Tolperisone for the treatment of acute muscle spasm of the back: results from the dose-ranging Phase II STAR Study (NCT03802565). J. Pain Res.13, 3059–3069 (2020).
   PubMed Web of Science ®Google Scholar